Erwin Blomsma, Chairman of the Board of Directors of flanders.bio: ‘For the successful rollout of our strategy, it is important to be able to rely on a diversity of knowledge and expertise at the various levels of our organization. We would therefore like to welcome the new directors and look forward to fully utilizing their expertise to support the booming life sciences sector in our region.’
Among others, Sanofi and Biocartis will support the further implementation of the strategy of flanders.bio. Jo Dalle, Head of New Product Introduction of Sanofi: ‘Sanofi is an innovative organization that has expanded its activities in Flanders in recent years, both in terms of production, with the expansion of the production site in Geel, and in terms of research and development with the acquisition of Ablynx, one of the biggest success stories in the Flemish biotech sector. Participation in the board of directors of flanders.bio is a way for Sanofi to actively contribute to the strong ecosystem for life sciences in Flanders. For example, we are closely involved in the training programs of flanders.bio, because our sector needs a continuous influx of new talent with good technical knowledge and the right mindset.’
Herman Verrelst, CEO of Biocartis: ‘The life sciences sector is undergoing major developments at an unprecedented pace today, with new technologies and health solutions taking a prominent place in the market. Flanders is at the forefront of life sciences and technology, including the presence of global players in research fields such as VIB and imec and with a highly innovative industrial ecosystem. Everything is there to build the health solutions of the future and Biocartis looks forward to actively contributing together with flanders.bio. ‘
